Months of discreet talks point to a potentially transformative proposal, but insiders warn the deal could still fall apart before any agreement.<\/p>\n
On August 2, Reuters reported that the British pharmaceutical company AstraZeneca is considering a possible merger with the American competitor Bristol Myers Squibb. According to the Financial Times, citing people close to the matter, the talks concern a potential deal.<\/p>\n
The publication estimates that such a deal could create one of the world\u2019s largest pharmaceutical groups, with a combined value of about $400 billion.<\/p>\n
The FT article notes that the companies have been in talks about a possible merger over the past few months, and the deal could materialize in the near term, but it could also be postponed or terminated.<\/p>\n
Reuters was not able to confirm the information immediately. AstraZeneca declined to comment, and Bristol Myers Squibb did not respond to Reuters\u2019 request outside of business hours.<\/p>\n
Last year, AstraZeneca announced plans for a direct listing in the United States to capitalize on higher valuations there, while remaining listed on the London Stock Exchange.<\/p>\n
The company\u2019s shares, under Pascal Soriot\u2019s 14-year tenure, have more than quadrupled, outpacing the broader FTSE 100 and its main British competitor GSK.<\/p>\n
According to the results of the second quarter reported last week, demand for oncology and rare-disease therapies has been rising, supporting growth. Oncology medicines accounted for about $25 billion in sales in 2025, nearly half of the total; other areas \u2013 cardiovascular, renal and metabolic drugs \u2013 were valued at around $12 billion.<\/p>\n
Negotiations are ongoing, but their final outcome will remain uncertain until an agreement is reached or the deal is abandoned.<\/p>\n","protected":false},"excerpt":{"rendered":"Months of discreet talks point to a potentially transformative proposal, but insiders warn the deal could still fall…\n","protected":false},"author":2,"featured_media":95947,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[40796,11153,40797,40795,40798,18,40799,40800],"class_list":["post-95946","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-400-billion-deal","tag-astrazeneca","tag-astrazeneca-merger","tag-astrazeneca-merger-bristol-myers-squibb-pharma-ma-400-billion-deal-oncology-portfolio","tag-bristol-myers-squibb","tag-news","tag-oncology-portfolio","tag-pharma-ma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117028344591402157","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/95946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=95946"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/95946\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/95947"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=95946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=95946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=95946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}